The Effects of MLS LASER Therapy in Patients With Chronic Nonspecific Low Back Pain
MLSLASERlumb
Pilot Study on the Effects of MLS (Multiwave Locked System) LASER Therapy in Patients With Chronic Nonspecific Low Back Pain: Randomized Controlled Trial Versus Placebo
1 other identifier
interventional
50
1 country
1
Brief Summary
Non-specific cronic low back pain is very common condition affecting 80-85% of adults. The most common therapies for low back pain are: patient education, excercise and physical therapy. High intensity laser therapy has been shown to be an effective treatment to improve sympthoms in patient with non-specific low back pain when combined wth exercise. The aim of this study is to assess the effects of a multi-wave locked system laser therapy in patient with non-specif low back pain when administered alone.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Mar 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 21, 2022
CompletedFirst Submitted
Initial submission to the registry
June 27, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 21, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
March 21, 2023
CompletedFirst Posted
Study publicly available on registry
May 23, 2023
CompletedMay 25, 2023
May 1, 2023
1 year
June 27, 2022
May 23, 2023
Conditions
Outcome Measures
Primary Outcomes (3)
Low back pain
VAS, Visual Analogic Scale minimum 0 (the best) and maximum 10 (the worst)
At baseline (T0)
Low back pain
VAS, Visual Analogic Scale minimum 0 (the best) and maximum 10 (the worst)
3 weeks (T1)
Low back pain
VAS, Visual Analogic Scale minimum 0 (the best) and maximum 10 (the worst)
One month by the end of the intervention (T2)
Secondary Outcomes (6)
Disability
At baseline (T0)
Disability
3 weeks (T1)
Disability
One month by the end of the intervention (T2)
Pain and Disability
At baseline (T0)
Pain and Disability
3 weeks (T1)
- +1 more secondary outcomes
Other Outcomes (6)
Trunk kinematics
At baseline (T0)
Trunk kinematics
3 weeks (T1)
Trunk kinematics
One month by the end of the intervention (T2)
- +3 more other outcomes
Study Arms (2)
Sham laser therapy
SHAM COMPARATORThe control group (PL group) is subjected to a laser sham (placebo), employing a device identical to the one under investigation but lacking the laser emission capability, and the same mode of administration in terms of time and place. Both the sham laser and the test device emit visible light of the same color and are not distinguishable in any way.
Laser therapy
EXPERIMENTALThe MLS group receives MLS synchronized diode laser therapy emitted by the MLS M8 robotic device (ASA, Italy). MLS M8 (ASA, Arcugnano, Italy), a Class IV (high-power) laser approved by the Food Drug Administration (FDA) and CE certified, characterized by a combined, synchronized two-wavelength (CPW) emission: a continuous emission with a wavelength of 808 nm and a pulsed emission at 905 nm. The duration of each session is 5 min 45 sec.seconds, delivering a total energy of 1500 J and an energy dose of 5 J/cm2, for an area of 300 cm2. The robotic device is placed in the lumbar area, oriented on the muscles erector spinae and quadratus lumborum. The target area set on the device is "lumbar area." The parameters set on the device are "Synchronized Emission of Continuous Pulsed Wave (CPW)," "intensity of 100%," "time of 5 minutes and 45 seconds," and "area of 1x300 cm2."
Interventions
Eligibility Criteria
You may qualify if:
- Chronic low back pain (\> 3 months)
- Lack of effectivness of previous conservative therapies for low back pain
- Body mass index \< 30
- Preserved cognitive ability to fully understand and observe indications received by medical personnel
- Ability to understand and give an informed consent
You may not qualify if:
- Spine surgery
- Spinal hernia
- spondylolisthesis
- Spinal infections
- Severe spine deformities
- Neural diseases
- Rheumatic diseases
- Diabetes
- Psychiatric diseases
- Vascular diseases
- Cancer
- Infectious diseases
- Kidney stones
- Skin abrasion
- Pregnancy or breastfeeding
- +14 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
IRCCS-Istituto Ortopedico Rizzoli
Bologna, 40136, Italy
Study Officials
- PRINCIPAL INVESTIGATOR
Maria Grazia Benedetti
Istituto Ortopedico Rizzoli
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, CARE PROVIDER
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of the Unit of Physical Medicine and Rehabilitation
Study Record Dates
First Submitted
June 27, 2022
First Posted
May 23, 2023
Study Start
March 21, 2022
Primary Completion
March 21, 2023
Study Completion
March 21, 2023
Last Updated
May 25, 2023
Record last verified: 2023-05